A True Confession About Indian Biotech

Where we think the science, the capital, and the country are actually going — and what we're betting on. This is Speciale's view, not the market's.

---

Every year a number gets read out at a podium in Delhi and the room applauds. This time it was $195.3 billion — India's bioeconomy, up 18% in a single year, now around 4.8% of GDP, built on the backs of nearly 12,000 biotech startups. It is a genuinely large, genuinely good number.

It is also, if we're being honest, the wrong place to start a conversation about Indian biotech.

We invest at the depth of science. That forces a certain kind of honesty on us, because the science doesn't care about the headline. So consider this a confession — about what that number hides, about why we're bullish anyway, and about the specific things in biology we find genuinely exciting right now. None of this is consensus. It's ours.

The number is four businesses wearing one costume

When you decompose the $195.3 billion, you don't find one industry. You find four, and they have almost nothing to do with each other.

BioIndustrial (~$90B) — ethanol blending, biofuels, enzymes, bio-based materials. Nearly half the total. This is a commodity, manufacturing, margin-and-scale business. It is closer to a refinery than to a lab.

BioPharma (~$65B) — vaccines, biosimilars, the generics-and-biologics export machine. Real and world-class, but mostly built on making known molecules cheaper and at scale, not discovering new ones.

BioServices (~$26B) — CROs, clinical trials, the GCCs, bioinformatics. Selling the world's pharma industry our scientists' time. A services business.

BioAgri (~$15B) — Bt cotton, biofertilisers, biopesticides. The smallest slice.

Three of those four are, fundamentally, cost-and-scale businesses. India is extraordinary at them — that's the whole story of the last two decades. But "we make the world's medicine cheaply" and "we discover the world's medicine" are different sentences. Different capital structures, different risk profiles, different national capabilities. Lumping them under one triumphant number lets everyone avoid the uncomfortable question: how much of that $195 billion is novel science, and how much is excellent execution on someone else's science?

The honest answer is that the innovation layer — first-in-class molecules, new modalities, platforms that generate IP rather than rent it — is the smallest and hardest of the four curves. It barely moves the headline. It is also the only one that compounds into something the rest of the world has to come to India to buy.

That's the curve we care about. And it's the one the bioeconomy number is least equipped to talk about.

Why we're bullish anyway, lessons from past 

Here is the thing that makes us bullish, and it isn't the number. It's the timing.

We think India in 2026 is sitting roughly where China sat in 2015–16: at the moment a state decides to put its foot down and build the bone for innovative biology — before the output shows up in any chart.

The Chinese inflection wasn't a discovery. It was a policy document. In August 2015, the State Council issued a wholesale overhaul of how drugs got reviewed and approved. China joined the ICH in 2017, restructured its regulator into the NMPA in 2018, and built priority, breakthrough, and conditional approval pathways from scratch. For years it looked like paperwork. Then the output arrived: China approved 48 first-in-class medicines in 2024, up from 21 in 2022, and Chinese biotech became a net exporter of molecules to Western pharma. The decade between the policy and the payoff is the part everyone forgets.

Bio is the hardest deeptech to fund privately, and the reason is structural. The experiments are expensive, the timelines are long, and the risk-reward is brutally non-linear, most programs return nothing and a few return everything, on a clock measured in years. Venture capital alone cannot carry a country across that valley. You need patient, deep, partly-public pockets to build the bone: the shared infrastructure, the early de-risking capital, the willingness to fund the thing that won't pay back for a decade.

This is exactly where policy and state capital matter more in bio than almost anywhere else in deeptech. And this is the part where, frankly, we're grateful.

BioE3 (2024) was the signal — Biotechnology for Economy, Environment and Employment, pointed at high-performance biomanufacturing and frontier areas from precision therapeutics to bio-based chemicals to marine and space biotech. The statement of intent.

The RDI Scheme is the money. Approved July 2025 and launched that November, it commits ₹1 lakh crore (~$12B) over six years — ₹20,000 crore in the first year alone — routed through the ANRF to second-level fund managers like BIRAC and the Technology Development Board, as long-tenure low-or-nil-interest loans and equity, covering up to half of project cost for TRL-4-and-above work. Concessional, patient capital aimed precisely at the lab-to-market valley that has always swallowed Indian science.

Whatever the execution turns out to be — and execution is everything — the shape of this is right. A government deciding to underwrite high-risk, long-horizon science with patient capital is the single most important precondition for an innovative biotech ecosystem. It's the foot going down. We don't yet know everything BioE3 and the RDI fund will open up, and that uncertainty is the exciting part.

What we're genuinely excited about

The most honest section of any confession. Here is what we actually find interesting in biology right now — not the safe bets, the ones we'd write checks against.

1. India's right to win is in modality access, not molecule discovery — yet. Every modality eventually commoditizes. Small molecules did. Antibodies did. Cell and gene therapy, ADCs, and RNA are next. When a modality matures, the advantage shifts from who invented it to who can make it work at Indian cost. India's structural edge is being the place that takes a proven-but-expensive modality and collapses its price — CAR-T delivered at a fraction of the Western cost is the live example. That isn't a consolation prize. It's how you build the muscle and the cash flow to eventually discover — the same way services funded China's leap.

2. The discovery process itself is becoming an engineering problem. AI models, lab automation, and cheap reads and writes of biology are turning drug discovery from artisanal to industrial — a recursive factory where each cycle of design–build–test–learn feeds the next. India has a rare combination to build this: world-class computational talent, a deep bench of wet-lab scientists, and a cost base that makes running thousands of cycles affordable. The country that industrialises discovery, not just manufacturing, wins the next curve. We think that platform can be built here.

3. The boring infrastructure under the science. Reagents, instruments, assays, bioprocess tooling, the data layer. Unglamorous, capital-efficient, and a precondition for everything above it. China built its biotech on a domestic supply chain; India still imports most of its picks and shovels. That gap is an opportunity.

4. Specific scientific frontiers we're watching closely. In vivo cell therapy — making CAR-T inside the patient instead of in a manufacturing suite, which would demolish the cost structure of the entire category. Drugging the previously undruggable, like pan-RAS. Next-generation antibody and bispecific platforms. Indian-origin genome-editing tools. These are the readouts and platforms we're closely watching now, and the ones we think a generational Indian biotech company could be built around.

We could be wrong about any of these. That's the job. But these are the directions where the science, the cost structure, and the policy tailwind line up,  a rare alignment, and the whole reason we're writing this down.

Final Ode

A confession should end with the things we can't yet answer.

What we do know is the direction. The policy is right, the capital is arriving, the science is ready, and the cost advantage is real. The question was never whether India can make biology cheaply. It's whether India decides to discover. We think that decision is being made right now — and we want to back the founders making it.

That's our confession. We're at the start of something, we're grateful to the people building the bone, and we're putting our capital where we think the curve actually bends.

This is our view, not the market's. We'd love to be argued with.

— Speciale Invest